Revolutionary New Therapy for a Deadly Form of Leukemia

by Aishwarya Radhakrishnan on  July 17, 2017 at 9:56 PM Research News
RSS Email Print This Page Comment bookmark
Font : A-A+

Stand Up To Cancer and the St. Baldrick's Foundation welcomed the Oncology Drugs Advisory Committee's (ODAC) strong recommendation for approval by the Food and Drug Administration (FDA) of a revolutionary new therapy for a deadly form of leukemia, an approach whose development has also been supported by SU2C and St. Baldrick's.
Revolutionary New Therapy for a Deadly Form of Leukemia
Revolutionary New Therapy for a Deadly Form of Leukemia

"When fully commercialized, this therapy will no doubt save the lives of many children and young adults who have had no other effective therapy for relapsed and refractory B-cell acute lymphoblastic leukemia (ALL)," said John Maris, MD, a pediatric oncologist at The Children's Hospital of Philadelphia who holds the Giulio D'Angio Chair in Neuroblastoma Research, and leader of the SU2C-St. Baldrick's Pediatric Cancer Dream Team. "This is truly a turning point in the management of this disease."

"SU2C and the St. Baldrick's Foundation have committed millions of dollars to the development of the chimeric antigen receptor (CAR) T cell therapy," said Sung Poblete, PhD, RN, president and CEO of SU2C.

"The team also played a major role in developing standardized management of cytokine release syndrome (CRS), a potentially fatal side effect of the treatment," added Lee J. Helman, MD, director of the Cancer Research Program at the Saban Institute at Children's Hospital of Los Angeles and a member of SU2C's Scientific Advisory Committee.

"We are very proud that we are playing a key role in the overall development of CAR T cell therapy, and hope that the treatment will soon be available to children and young adults around the world," said Crystal L. Mackall, MD, professor of pediatrics and internal medicine at Stanford University, associate director of Stanford Cancer Institute, and co-leader of the Dream Team.

"The St. Baldrick's Foundation has been an early supporter of bringing new immunotherapy approaches to childhood cancer, and this Dream Team is the largest of these grants," said Chief Mission Officer Becky Chapman Weaver. "Children are alive today because of this crucial research."

The Oncology Drugs Advisory Committee (ODAC) voted 10-0 Wednesday to recommend that FDA approve a biologics license application (BLA) from the pharmaceutical company Novartis for tisagenlecleucel (CTL019) for the treatment of patients aged 3 to 25 years old with relapsed/refractory B-cell acute lymphoblastic leukemia. The FDA will take up the application in the near future.



Source: Eurekalert
Advertisement

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Leukemia Chronic Myeloid Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Reiki and Pranic Healing Multiple Myeloma Amyotrophic Lateral Sclerosis (ALS) Bone Marrow Transplantation Hairy Cell Leukemia Acute Coronary Syndrome 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...